Literature DB >> 24778130

Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Richard W Joseph1, Mansi Parasramka, Jeanette E Eckel-Passow, Dan Serie, Kevin Wu, Liuyan Jiang, Krishna Kalari, R Houston Thompson, Thai Huu Ho, Erik P Castle, John Cheville, Eugene D Kwon, E Aubrey Thompson, Alexander Parker.   

Abstract

Increased angiogenesis and tumor-induced immune evasion are two mechanisms by which clear cell renal cell carcinoma (ccRCC) proliferate and metastasize; however, the relationship between these pathways in human ccRCC is poorly understood. We conducted a nested case-control study using 98 archived tumor samples from patients diagnosed with primary ccRCC between 1990 and 2006, half of which were identified by immunohistochemistry (IHC) as either programmed death ligand 1 (PDL-1)-positive or PDL-1-negative. RNAs were extracted from the formalin-fixed paraffin-embedded tumor slides and the expression of the VEGFA, VEGFR1, VEGFR2, and PDL-1 genes was quantified. We assessed the presence of tumor-infiltrating lymphocytes (TIL) by IHC for CD3, and then analyzed the relationship among VEGFA, VEGFR1, VEGFR2, CD3, and PDL-1. When analyzed as a continuous variable, PDL-1 protein expression by IHC inversely correlates with the expression of the three VEGF-related genes: VEGFA (r = -0.23; P = 0.01), VEGFR1 (r = -0.34; P < 0.001), and VEGFR2 (r = -0.23; P = 0.01). When dichotomized, the PDL-1-positive cohort trended toward a lower expression of VEGFA (fold change = 0.72; P = 0.056) and VEGFR1 (fold change = 0.69; P = 0.057). In addition, there was a significant and positive relationship between the presence of TIL as assessed by IHC for CD3 and PDL-1 by IHC (r = 0.25; P = 0.015), and there was a trend toward an inverse relationship between TIL and VEGFA gene expression (r = -0.18; P = 0.089). In conclusion, this is the first demonstration of an inverse association between the angiogenesis and PDL-1 pathways in tumor samples from primary ccRCC, and this relationship may be related to the immunosuppressive effects of VEGF signaling. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24778130      PMCID: PMC4322777          DOI: 10.1158/2326-6066.CIR-13-0042

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  27 in total

1.  Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.

Authors:  R Houston Thompson; Bradley C Leibovich; Christine M Lohse; John C Cheville; Horst Zincke; Michael L Blute; Igor Frank
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 3.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

4.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

Authors:  R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Kent G Krejci; John R Lobo; Shomik Sengupta; Lieping Chen; Horst Zincke; Michael L Blute; Scott E Strome; Bradley C Leibovich; Eugene D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

5.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Authors:  Andrew T Parsa; James S Waldron; Amith Panner; Courtney A Crane; Ian F Parney; Jeffrey J Barry; Kristine E Cachola; Joseph C Murray; Tarik Tihan; Michael C Jensen; Paul S Mischel; David Stokoe; Russell O Pieper
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

6.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Authors:  R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

7.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

8.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

Authors:  J G Herman; F Latif; Y Weng; M I Lerman; B Zbar; S Liu; D Samid; D S Duan; J R Gnarra; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

9.  Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma.

Authors:  Amy E Krambeck; Haidong Dong; R Houston Thompson; Susan M Kuntz; Christine M Lohse; Bradley C Leibovich; Michael L Blute; Thomas J Sebo; John C Cheville; Alexander S Parker; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

10.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

View more
  14 in total

Review 1.  Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?

Authors:  Susanne Lütje; Georg Feldmann; Markus Essler; Peter Brossart; Ralph A Bundschuh
Journal:  J Nucl Med       Date:  2020-01-10       Impact factor: 10.057

Review 2.  Advancing Immunotherapy in Metastatic Breast Cancer.

Authors:  Mariam Mansour; Zhi Ling Teo; Stephen J Luen; Sherene Loi
Journal:  Curr Treat Options Oncol       Date:  2017-06

3.  Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma.

Authors:  Fuyou Zhao; Qiong Wu; Xiusong Dai; Yumei Li; Huaiyong Gan; Ri Wang; Jie Lv; Yuqing Chen
Journal:  Oncol Lett       Date:  2016-10-24       Impact factor: 2.967

Review 4.  Molecular and Circulating Biomarkers in Patients with Glioblastoma.

Authors:  Nadia Senhaji; Asmae Squalli Houssaini; Salma Lamrabet; Sara Louati; Sanae Bennis
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

Review 5.  Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Authors:  Pierre Combe; Eleonore de Guillebon; Constance Thibault; Clémence Granier; Eric Tartour; Stéphane Oudard
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

6.  PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

Authors:  Richard W Joseph; Sherri Z Millis; Estrella M Carballido; David Bryant; Zoran Gatalica; Sandeep Reddy; Alan H Bryce; Nicholas J Vogelzang; Melissa L Stanton; Erik P Castle; Thai H Ho
Journal:  Cancer Immunol Res       Date:  2015-08-25       Impact factor: 11.151

7.  Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.

Authors:  Song Xue; Man Hu; Peifeng Li; Ji Ma; Li Xie; Feifei Teng; Yufang Zhu; Bingjie Fan; Dianbin Mu; Jinming Yu
Journal:  Oncotarget       Date:  2017-07-25

8.  The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis.

Authors:  Jiao Wang; ChangXin Shen; YouRong Fu; Tian Yu; JingJing Song
Journal:  Onco Targets Ther       Date:  2017-03-21       Impact factor: 4.147

9.  Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.

Authors:  Giosuè Scognamiglio; Anna De Chiara; Maurizio Di Bonito; Fabiana Tatangelo; Nunzia Simona Losito; Annamaria Anniciello; Rossella De Cecio; Crescenzo D'Alterio; Stefania Scala; Monica Cantile; Gerardo Botti
Journal:  Int J Mol Sci       Date:  2016-05-21       Impact factor: 5.923

10.  Downregulation of VEGFA inhibits proliferation, promotes apoptosis, and suppresses migration and invasion of renal clear cell carcinoma.

Authors:  Fan-Chang Zeng; Ming-Qiang Zeng; Liang Huang; Yong-Lin Li; Ben-Min Gao; Jun-Jie Chen; Rui-Zhi Xue; Zheng-Yan Tang
Journal:  Onco Targets Ther       Date:  2016-04-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.